Ticker Symbol: IMPL
Impel Pharmaceuticals Inc
$10.80 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001445499
Company Profile
Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Standard Industrial Classification Code (SIC code): 2834
Address: 201 ELLIOTT AVE. W
Website: impelnp.com
CEO: Michael Hite
Tags:
N/A
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $0.41
Change:
$0.01
(
4.80%)
Days Range: $0.38 - $0.43
Beta: 0.50
52wk. High: $4.34
52wk. Low: $0.27
Ytd. Change -84.75%
50 Day Moving Average: $0.46
200 Day Moving Average: $1.14
Shares Outstanding: 23749005
Valuation
Market Cap: 975.6M
PE Ratio: -0.11
EPS (TTM): -3.86
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A